A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
Public ClinicalTrials.gov record NCT04129164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
Study identification
- NCT ID
- NCT04129164
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- VIB4920 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2019
- Primary completion
- Aug 31, 2022
- Completion
- Mar 9, 2023
- Last update posted
- Apr 29, 2025
2019 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fullerton | California | 92835 | — |
| Research site | Upland | California | 91786 | — |
| Research Site | Lawrenceville | Georgia | 30046 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Wheaton | Maryland | 20902 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Salisbury | North Carolina | 28144 | — |
| Research Site | Wilmington | North Carolina | 28401 | — |
| Research site | Duncansville | Pennsylvania | 16635 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research site | Dallas | Texas | 75231 | — |
| Research Site | Houston | Texas | 77084 | — |
| Research Site | Houston | Texas | 77089 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04129164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04129164 live on ClinicalTrials.gov.